Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy.

It is unclear whether hepatitis B surface antibody (HBsAb) confers clinical benefits after HBsAg seroclearance, especially in hepatitis B surface antigen (HBsAg) seroreversion and maintenance of HBsAb. We evaluated this in patients (n = 222) with HBsAg loss following treatment with pegylated interferon (PEG-IFN)-based therapy who completed a 48-week follow-up period. Serum hepatitis B virus (HBV) markers and biochemical indicators were evaluated every 3 months. The primary endpoint was HBsAg seroreversion. Factors associated with HBsAg seroreversion were also investigated. HBsAb ≥100 mIU/ml resulted in a lower HBsAg seroreversion rate than an HBsAb-negative status (5.5% vs. 29.5%, p < .001); however, the seroreversion rate was not significantly different between patients with HBsAb 10-100 mIU/ml and those in the HBsAb-negative group. Patients with HBsAb ≥100 mIU/ml had a lower HBsAb loss rate than those with HBsAb 10-100 mIU/ml (7.3% vs. 21.7%, p = .005). The final HBsAg seroreversion and HBV DNA relapse rates were 13.5% and 1.8%, respectively. HBsAb ≥100 mIU/ml at the off-treatment time (odds ratio [OR] 0.110, 95% confidence interval [CI]: 0.034-0.353, p < .001) and treatment time to attain HBsAg loss >28 weeks (OR 2.508, 95% CI: 1.068-5.890, p = .035) were predictors of HBsAg seroreversion. Consolidation therapy for 12-24 weeks resulted in higher HBsAb titres than consolidation therapy for ≤12 weeks in HBsAb-negative patients at the off-treatment time (p < .001). HBsAg seroconversion with HBsAb ≥100 mIU/ml decreases HBsAg seroreversion and provides an efficient maintenance rate of HBsAb. HBsAg seroconversion with high HBsAb titres may be clinically beneficial for chronic hepatitis B treated with PEG-IFN-based therapy.

Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.

Combination therapy with pegylated interferon (PEG-IFN) and nucleos(t)ide analogues (NAs) can enhance hepatitis B surface antigen (HBsAg) clearance. However, the specific treatment strategy and the patients who would benefit the most are unclear. Therefore, we assessed the HBsAg loss rate of add-on PEG-IFN and explored the factors associated with HBsAg loss in chronic hepatitis B (CHB) patients. This was a real-world cohort study of adults with CHB. Hepatitis B e antigen (HBeAg)-negative NAs-treated patients with baseline HBsAg ≤1500 IU/ml and HBV DNA < the lower limit of detection, or 100 IU/ml, received 48 weeks of add-on PEG-IFN. The primary outcome of the study was the rate of HBsAg loss at 48 weeks of combination treatment. Using multivariable logistic regression analysis, we determined factors associated with HBsAg loss. HBsAg loss in 2579 patients (mean age: 41.2 years; 80.9% male) was 36.7% (947 patients) at 48 weeks. HBsAg loss was highest in patients from south-central and southwestern China (40.0%). Factors independently associated with HBsAg loss included: increasing age (odds ratio = 0.961); being male (0.543); baseline HBsAg level (0.216); HBsAg decrease at 12 weeks (between 0.5 and 1.0 log10 IU/ml [2.405] and >1.0 log10 IU/ml [7.370]); alanine aminotransferase (ALT) increase at 12 weeks (1.365); haemoglobin (HGB) decrease at 12 weeks (1.558). There was no difference in the primary outcomes associated with the combination regimen. In conclusion, HBsAg loss by combination therapy was higher in patients from southern China than those from the north. An increased chance of HBsAg loss was associated with baseline characteristics and dynamic changes in clinical indicators.

Stabilization of FAPbI3 with Multifunctional Alkali-Functionalized Polymer.

The defects located at the interfaces and grain boundaries (GBs) of perovskite films are detrimental to the photovoltaic performance and stability of perovskite solar cells. Manipulating the perovskite crystallization process and tailoring the interfaces with molecular passivators are the main effective strategies to mitigate performance loss and instability. Herein, a new strategy is reported to manipulate the crystallization process of FAPbI3 -rich perovskite by incorporating a small amount of alkali-functionalized polymers into the antisolvent solution. The synergic effects of the alkali cations and poly(acrylic acid) anion effectively passivate the defects on the surface and GBs of perovskite films. As a result, the rubidium (Rb)-functionalized poly(acrylic acid) significantly improves the power conversion efficiency of FAPbI3 perovskite solar cells to approaching 25% and reduces the risk of lead ion (Pb2+ ) leakage continuously via the strong interaction between CO bonds and Pb2+ . In addition, the unencapsulated device shows enhanced operational stability, retaining 80% of its initial efficiency after 500 h operation at maximum power point under one-sun illumination.

Poly(vinyl alcohol)/phosphoric acid gel electrolyte@polydimethylsiloxane sponge for piezoresistive pressure sensors.

Piezoresistive pressure sensors based on flexible, ultrasensitive, and squeezable conductive sponges have recently attracted significant attention. However, the preparation of cost-effective conductive sponges with good stability and wide strain range for pressure sensing remains a challenge. Herein, a conductive poly(vinyl alcohol)/phosphoric acid gel electrolyte@polydimethylsiloxane (PVA/H3PO4@PDMS) composite was fabricated by impregnating a PDMS sponge into a PVA/H3PO4 gel electrolyte. The conductivity of the as-prepared sponges was determined using a gel electrolyte polymer film. The sponge exhibited good sensitivity of 0.1145 kPa-1 in the low-pressure range (0-6.5 kPa), short response time (70 ms), and durability for over 2700 s (6000 cycles). The gauge factor of the PVA/H3PO4@PDMS sponge was 5.51, 1.49, and 0.33 at the strain range of 0-10%, 10-30%, and 30-80%, respectively. Based on these outstanding sensing performances, the sponges were applied for the detection of various human motions, such as vocal cord vibration, joint bending, respiratory rate, and pulse signal detection. Further, the sponge demonstrated their great potential in the fabrication of electronic skin and high-performance flexible wearable electronics. Therefore, the obtained PVA/H3PO4 gel electrolyte used as a sponge conductive coating material is a readily available and inexpensive material that can reduce the cost of composite materials for pressure sensing.

A bioinspired porous-designed hydrogel@polyurethane sponge piezoresistive sensor for human-machine interfacing.

Conductive coating sponge piezoresistive pressure sensors are attracting much attention because of their simple production and convenient signal acquisition. However, manufacturing sponge-structure pressure-sensing materials with high compressibility and wide pressure detection ranges is difficult because of the instability of rigid and brittle conductive coatings at large strains. Herein, a tough conductive hydrogel@polyurethane (PU) sponge with a porous design is prepared via immersion of a polyurethane sponge in a low-cost and biocompatible polyvinyl alcohol (PVA)/glycerin (Gl)/sodium chloride (NaCl) solution. The sensor based on the hydrogel/elastomer sponge composite material exhibits a compressible range of 0-93%, a pressure detection range of 100 Pa-470.2 kPa, and 10 000-cycle stability (80% strain) because of the compressibility, flexibility, and toughness of the porous hydrogel coating. Benefiting from the resistance change mechanism of microporous compression, the sensor also exhibits a wide range of linear resistance changes, and the corresponding sensitivity and gauge factor (GF) are -0.083 kPa-- (100 Pa-10.0 kPa) and -1.33 (1-60% strain), respectively. Based on its flexibility, compressibility, and wide-ranging linear resistance changes, the proposed sensor has huge potential application in human activity monitoring, electronic skin, and wearable electronic devices.